INTRAVENOUS VERSUS SUBCUTANEOUS TOCILIZUMAB IN A SERIES OF 471 PATIENTS WITH GIANT CELL ARTERITIS Conference Poster 2022 Congress communication uri icon

publication date

  • 2022